Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 Study of GSK5764227 in Previously Treated Advanced Gastrointestinal Solid Tumors
jRCT2011250008Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of risvutatug rezetecan in colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC) and Not applicable (2 cohorts), sponsored by GSK. Primary endpoint: Confirmed Objective Response Rate (ORR). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
colorectal adenocarcinomapancreatic adenocarcinoma (PDAC)Not applicable
Beyond the preview
Go deeper on jRCT2011250008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250008.